T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
multicentric Castleman disease Rituximab as retreatment for rituximab pretreated HIV-associated
Mark Bower,Thomas Powles,Justin Stebbing,Silvia Montoto,Mark Nelson,Brian Gazzard,Chloe Orkin,Andrew Webb +7 more
Proceedings ArticleDOI
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Thomas Powles,R. van den Heuvel +1 more
Journal ArticleDOI
Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.
Peter H. O'Donnell,Arjun Vasant Balar,Daniel Castellano,Ronald de Wit,David J. Vaughn,Thomas Powles,Jacqueline Vuky,Jae-Lyun Lee,Yves Fradet,Joaquim Bellmunt,Lawrence Fong,Daniel P. Petrylak,Winald R. Gerritsen,David I. Quinn,Stéphane Culine,Dean F. Bajorin,Jin Zhi Xu,Kentaro Imai,Blanca Homet Moreno,Petros Grivas +19 more
TL;DR: In this exploratory analysis, pembro showed similar clinical activity and manageable safety regardless of primary UC tumor location, and in the chemo arm of KEYNOTE-045, similar efficacy was observed regardless of tumor location or regimen.
Journal ArticleDOI
Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
Jeffrey J. Leow,Yew Lam Chong,Steven L. Chang,Begoña P. Valderrama,Thomas Powles,Joaquim Bellmunt +5 more